Quick Answer
Korro Bio, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $0.00 for the year ending 2022.
- Korro Bio, Inc. showed a decrease of -100.0% in Revenue From Contract With Customer Excluding Assessed Tax from 2021 to 2022.
- This data is from Korro Bio, Inc.'s annual report (Form 10-K), filed with the SEC on March 10, 2023.
- XBRL data for this metric is available from 2019 to 2022 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: $24.24 million | Q4 2019: $4.71 million | Q1 2020: $7.26 million | Q2 2020: $8.52 million | Q3 2020: $11.25 million | Q4 2020: $9.95 million | Q1 2021: $4.65 million | Q2 2021: $9.42 million | Q3 2021: $0.00 | Q1 2022: $0.00 | Q2 2022: $0.00 | Q3 2022: $0.00.
- Over the full 4 years of available data (2019 to 2022), Korro Bio, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has declined by 100.0%.
- Historical annual values: Fiscal year 2022: $0.00 | Fiscal year 2021: $14.07 million | Fiscal year 2020: $36.98 million | Fiscal year 2019: $28.95 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: